Agata Ptaszynska

5.5k total citations · 1 hit paper
42 papers, 4.1k citations indexed

About

Agata Ptaszynska is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Agata Ptaszynska has authored 42 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Endocrinology, Diabetes and Metabolism, 20 papers in Cardiology and Cardiovascular Medicine and 17 papers in Surgery. Recurrent topics in Agata Ptaszynska's work include Diabetes Treatment and Management (23 papers), Metabolism, Diabetes, and Cancer (13 papers) and Cardiovascular Function and Risk Factors (12 papers). Agata Ptaszynska is often cited by papers focused on Diabetes Treatment and Management (23 papers), Metabolism, Diabetes, and Cancer (13 papers) and Cardiovascular Function and Risk Factors (12 papers). Agata Ptaszynska collaborates with scholars based in United States, Sweden and Germany. Agata Ptaszynska's co-authors include Barry M. Massie, Peter E. Carson, Robert S. McKelvie, Michael R. Zile, John J.V. McMurray, Michel Komajda, James F. List, Shamik Parikh, C Staiger and Mark Donovan and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Agata Ptaszynska

39 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

2008 1.4k citations Barry M. Massie, Peter E. Carson et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Agata Ptaszynska United States	27	2.4k	2.0k	902	829	403	42	4.1k
Kieran F. Docherty United Kingdom	24	1.6k 0.7×	1.9k 1.0×	672 0.7×	825 1.0×	451 1.1×	113	3.4k
Brian Claggett United States	16	1.6k 0.7×	1.8k 0.9×	931 1.0×	738 0.9×	195 0.5×	32	3.4k
Richard M. Bittman United States	10	3.1k 1.3×	2.4k 1.2×	622 0.7×	1.5k 1.8×	833 2.1×	15	4.9k
George Sokos United States	15	1.6k 0.7×	1.2k 0.6×	542 0.6×	979 1.2×	473 1.2×	59	3.1k
Clare Arnott Australia	25	1.3k 0.6×	1.4k 0.7×	785 0.9×	788 1.0×	491 1.2×	117	3.4k
KyungAh Im United States	24	1.5k 0.7×	3.5k 1.8×	1.4k 1.5×	1.5k 1.8×	446 1.1×	47	4.7k
Jay H. Kleiman United States	14	3.8k 1.6×	2.9k 1.5×	736 0.8×	1.4k 1.7×	965 2.4×	20	5.5k
Barbara Roniker United States	16	4.0k 1.7×	3.9k 2.0×	958 1.1×	1.6k 1.9×	1.2k 2.9×	20	6.2k
Jennifer B. Green United States	31	1.5k 0.6×	3.6k 1.8×	1.4k 1.6×	1.3k 1.6×	290 0.7×	91	5.0k
Kasper Rossing Denmark	31	1.6k 0.7×	1.6k 0.8×	619 0.7×	448 0.5×	456 1.1×	89	4.1k

Countries citing papers authored by Agata Ptaszynska

Since Specialization

Citations

This map shows the geographic impact of Agata Ptaszynska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agata Ptaszynska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agata Ptaszynska more than expected).

Fields of papers citing papers by Agata Ptaszynska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agata Ptaszynska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agata Ptaszynska. The network helps show where Agata Ptaszynska may publish in the future.

Co-authorship network of co-authors of Agata Ptaszynska

This figure shows the co-authorship network connecting the top 25 collaborators of Agata Ptaszynska. A scholar is included among the top collaborators of Agata Ptaszynska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agata Ptaszynska. Agata Ptaszynska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russo, C Allison, et al.. (2017). PROGNOSTIC SIGNIFICANCE OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION PROGRESSION IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE I-PRESERVE TRIAL. Journal of the American College of Cardiology. 69(11). 885–885.

Yavin, Yshai, Traci A. Mansfield, Agata Ptaszynska, et al.. (2016). Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis. Diabetes Therapy. 7(1). 125–137. 52 indexed citations

Johnsson, Kristina, Eva Johnsson, Traci A. Mansfield, et al.. (2016). Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgraduate Medicine. 128(4). 346–355. 31 indexed citations

Fioretto, Paola, Traci A. Mansfield, Agata Ptaszynska, et al.. (2016). Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. Drugs & Aging. 33(7). 511–522. 37 indexed citations

Kohan, Donald E., et al.. (2016). The effect of dapagliflozin on renal function in patients with type 2 diabetes. Journal of Nephrology. 29(3). 391–400. 64 indexed citations

Ji, Linong, Jianhua Ma, Hongmei Li, et al.. (2014). Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study. Clinical Therapeutics. 36(1). 84–100.e9. 148 indexed citations

Weber, Michael A., Traci A. Mansfield, Caroline T'joen, & Agata Ptaszynska. (2013). Abstract 13165: Dapagliflozin for Reduction of Blood Pressure in Diabetic Patients Inadequately Controlled With Combination Antihypertensive Regimen. Circulation. 128. 3 indexed citations

Johnsson, Kristina, et al.. (2013). Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. Journal of Diabetes and its Complications. 27(5). 479–484. 173 indexed citations

Weber, Michael A., Traci A. Mansfield, Federica Alessi, & Agata Ptaszynska. (2013). Abstract 13144: Effects of Dapagliflozin on Blood Pressure in Diabetic Patients With Hypertension Inadequately Controlled by a Renin-Angiotensin System Blocker. Circulation. 128. 5 indexed citations

10.

Johnsson, Kristina, et al.. (2013). Urinary tract infections in patients with diabetes treated with dapagliflozin. Journal of Diabetes and its Complications. 27(5). 473–478. 170 indexed citations

11.

Basile, Jan, et al.. (2012). Abstract 59: The Effects of Dapagliflozin on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus. Circulation Cardiovascular Quality and Outcomes. 5(suppl_1). 1 indexed citations

12.

Henry, Robert R., et al.. (2012). Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. International Journal of Clinical Practice. 66(5). 446–456. 246 indexed citations

13.

Zile, Michael R., William H. Gaasch, Inder S. Anand, et al.. (2010). Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation. 121(12). 1393–1405. 252 indexed citations

14.

Komajda, Michel, Peter E. Carson, Scott Hetzel, et al.. (2010). Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. Circulation Heart Failure. 4(1). 27–35. 193 indexed citations

15.

Parhofer, Klaus G., Kåre I. Birkeland, Ralph A. DeFronzo, et al.. (2009). Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). International Journal of Clinical Practice. 64(2). 160–168. 7 indexed citations

16.

McMurray, John J.V., Peter E. Carson, Michel Komajda, et al.. (2008). Heart Failure with Preserved Ejection Fraction: Clinical Characteristics of 4133 Patients Enrolled in the I-PRESERVE Trial. European Journal of Heart Failure. 10(2). 149–156. 156 indexed citations

17.

Massie, Barry M., Peter E. Carson, John J.V. McMurray, et al.. (2008). Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine. 359(23). 2456–2467. 1362 indexed citations breakdown →

18.

NEUTEL, J, Stanley S. Franklin, Pablo Lapuerta, Amitabha Bhaumik, & Agata Ptaszynska. (2007). A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. Journal of Human Hypertension. 22(4). 266–274. 28 indexed citations

19.

Bakris, G., Luís M. Ruilope, Francesco Locatelli, et al.. (2007). Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney International. 72(7). 879–885. 76 indexed citations

20.

Neutel, Joel M., Stanley S. Franklin, Suzanne Oparil, et al.. (2006). Efficacy and Safety of Irbesartan/HCTZ Combination Therapy As Initial Treatment for Rapid Control of Severe Hypertension. Journal of Clinical Hypertension. 8(12). 850–859. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact